Tag : AD

CONFERENCE UPDATE

Abrocitinib achieves rapid and sustained symptom control in AD: Results from the 2nd interim analysis of the AHEAD study
Abrocitinib demonstrates rapid and sustained effectiveness in treating atopic dermatitis in Chinese patients, based on AHEAD study interim findings. Over 52 weeks, significant improvements in pruritus, skin lesions, QL, and reduced economic burden highlight its value as a long-term treatment for moderate to severe AD.
CONFERENCE UPDATE

AD linked to elevated suicidal ideation risk: Insights from a global epidemiology study
A global epidemiological study found that those with atopic dermatitis (AD) had a higher prevalence of SI compared to those without AD, regardless of onset age. The study also identified several demographic and clinical predictors for SI, emphasizing the importance of recognizing and managing suicide risk in patients with AD.
NEWS AND PERSPECTIVE

Dupilumab receives FDA approval for AD with moderate-to-severe hand and foot involvement based on data from the LIBERTY-AD-HAFT trial
Despite being approved for the treatment of moderate-to-severe atopic dermatitis (AD), dupilumab’s efficacy in treating patients with atopic hand and foot dermatitis had not been evaluated. The LIBERTY-AD-HAFT trial demonstrated dupilumab’s efficacy and safety in treating patients with AD with moderate-to-severe hand and foot involvement. Based on the study results, the United States (US) Food and Drug Administration (FDA) updated the label of dupilumab to include AD with moderate-to-severe hand and foot involvement.